ClinicalTrials.gg
CompletedNCT05245669Updated Dec 23, 2025Results posted

Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity of Biosimilar Denosumab With Prolia® in Healthy Adult Male Volunteers

A Phase 1 interventional study of ENZ215 and EU Sourced Prolia in Healthy Male Subjects, sponsored by Enzene Biosciences Ltd.. Completed at 2 sites in 2 countries. Open to male participants aged 28 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-23.

Sponsored by Enzene Biosciences Ltd. · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
207
Allocation
Randomized
Ages
28 Years to 55 Years
Sex
Male
01

Study summary

This is a randomized, double-blind, three-arm, parallel-group, single-dose study to demonstrate bioequivalence of ENZ215 and EU- and US-sourced Prolia after a single 60-mg dose administered subcutaneously in healthy adult male volunteers.

Read the detailed description

Approximately 207 subjects will be enrolled into 3 groups (69 in each group) in parallel. The subjects may be enrolled in multiple groups at the site. All eligible subjects will be assigned to one of the three treatment groups in 1:1:1 ratio i.e. ENZ215 or US-sourced Prolia® or EU-sourced Prolia® to enter into the study period of 39 weeks. The study duration will be approximately 16 months (i.e. 6 months of recruitment period, 4 weeks of screening period and approximately 39 weeks (270 days) of study period).

Each subject will be required to visit the site for a total of 20 visits: visit 1 - screening visit, visit 2 - day 0 to day 2, visit 3 - day 3, visit 4 - day 4, visit 5 - day 5, visit 6 - day 6, visit 7 - day 8, visit 8 - day 10, visit 9 - day 12, visit 10 - day 16, visit 11 - day 21, visit 12 - day 28 (week 4), visit 13 - day 42 (week 6), visit 14 - day 63 (week 9), visit 15 - day 90 (week 13), visit 16 - day 119 (week 17), visit 17 - day 147 (week 21), visit 18 - day 180 (week 26), visit 19 day - 224 (week 32), and visit 20 - day 270 (week 39). A window period of ±1 day is allowed for visit 12 (day 28), window period of ±3 days are allowed from day 42 (week 6) to day 180 (week 26), A window period of ±5 days are allowed from day 224 (week 32) to day 270 (week 39).

End of Study Assessment will be performed on day 270 (week 39) or at the time of early discontinuation of the subject.

02

Conditions studied

  • Healthy Male Subjects
03

In context

Lead sponsor

Enzene Biosciences Ltd. is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
28 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The subjects will be included in the study based on the following criteria:

  1. Able to understand and give written, voluntary for the study
  2. Healthy adult male volunteers between 28 to 55 years of age (both inclusive)
  3. (BMI) ≥ 18.50 and ≤ 30.00 kg/m2 at the time of screening
  4. Medically healthy with no medical history, vital signs, physical examination, and laboratory profiles
  5. Normal or clinically acceptable 12-lead , corrected for heart rate (QTc interval)* ≤ 450 msec at the time of screening
  6. Subjects with negative alcohol test (breath analyzer or any suitable test) at the time of screening and admission (pre-dose)
  7. Male subjects with female partners who agree to use effective during study#
  8. Male subjects who agree not to donate sperm during study
  9. Willing and able to comply with the protocol requirements
  10. Willing for multiple sampling and admission at the phase 1 study site day before dosing.

    • Note: QTc interval will be calculated using the Bazette and Fridericia formula.

      • Effective contraception: A non-vasectomised Male volunteers with female partners of child bearing potential should use dual method of contraception i.e. condom with spermicide method of contraception.

Female partners should use hormonal or non-hormonal method of contraception. (No restrictions are required for a vasectomised male provided his vasectomy has been performed 4 months or more prior to the first dosing. A male who has been vasectomised less than 4 months prior to the first dosing must follow the same restrictions as a non-vasectomised male).

Exclusion criteria

EXCLUSION CRITERIA

The subjects will be excluded from the study based on the following criteria:

  1. Known to Denosumab or to any of the components of the study drug
  2. Participating or has received any drug (or is currently using an investigational device) within 30 days before receiving the study drug, or at least 10 times the respective elimination halflife (whichever period is longer) *

    * For monoclonal antibody refer exclusion criteria number 18 and 19

  3. A serious infection (associated with housing and/or required intravenous anti-infectives) within 6 months before study drug administration and/or any active infection within 4 weeks of screening requiring oral or systemic antibiotics
  4. History of significant drug abuse within 12 months before screening or a use of soft drugs (such as marijuana) within 3 months before the screening visit or hard drugs (such as cocaine, phencyclidine, and crack etc.) within 12 months before screening
  5. Smokers who smoke ≥ 10 cigarettes or equivalent per day within 90 days prior to screening
  6. Subjects with positive urine screen for drugs of abuse at the time of screening or check-in
  7. Subjects with Urine Cotinine > 500ng/ml at the time of screening or check-in
  8. Subjects with risk of osteonecrosis of the jaw i.e. poor oral hygiene, periodontal disease, poorly fitting dentures, history of dental disease or have undergone invasive dental procedures e.g. tooth extractions within last 6 months prior to screening.
  9. Subjects with a predictable risk of invasive dental surgery during the 9 months after dosing or with planned invasive dental procedure
  10. Subjects with known bone disease or recent fracture or abnormalities of calcium metabolism
  11. Loss of blood (excluding volume drawn at screening) of 50 mL to 499 mL within 30 days, or more than 499 mL within 56 days before dosing
  12. History of immunodeficiency (including those subjects with a positive test for [HIV] at screening)
  13. Have a positive result for antigen test (HBsAg) or antibody test (HCAb), or show evidence of possible infection
  14. Major surgical procedure within 28 days of dose of investigational product.
  15. Male subjects having pregnant female partner at the time of screening.
  16. Subject with a history of recurrent or chronic infections
  17. Received within 4 weeks or who may require live vaccine(s) during the study duration
  18. Prior use of denosumab
  19. Have previously been exposed to a monoclonal antibody or fusion protein within 270 days (other than denosumab) prior to randomisation and/or there is confirmed evidence or clinical suspicion of immunogenicity from previous exposure to a monoclonal antibody or fusion protein.
  20. Any reason/condition which would preclude subject's participation in the study as per the Investigator's opinion or warnings and in the prescribing information of Prolia
  21. Subjects with suspected signs and symptoms of COVID-19/confirmed novel coronavirus infection (COVID-19).
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
207 participants (actual)

Study arms

  • Experimental
    ENZ215

    ENZ215 Injection:- 60 mg Denosumab (ENZ215) will be administered subcutaneously on day 1.

    Biological: ENZ215

  • Active comparator
    EU Sourced Prolia

    EU sourced Prolia Injection:- 60 mg Denosumab (EU sourced Prolia) will be administered subcutaneously on day 1.

    Biological: EU Sourced Prolia

  • Active comparator
    US Sourced Prolia

    US sourced Prolia Injection:- 60 mg Denosumab (US sourced Prolia) will be administered subcutaneously on day 1.

    Biological: US Sourced Prolia

Interventions

  • BiologicalENZ215

    healthy volunteers receive ENZ215 (60mg) once

  • BiologicalEU Sourced Prolia

    healthy volunteers receive Denosumab (60mg) once

  • BiologicalUS Sourced Prolia

    healthy volunteers receive Denosumab (60mg) once

06

What researchers measure

Primary outcomes

  1. Maximum Observed Drug Concentration (Cmax) of ENZ215 and EU- and US-sourced Prolia®

    A total of twenty four blood PK samples of 2.5 mL each were collected from each subject in the study. Pre-dose sample were collected within 30 minutes prior to IP administration. Post-dose samples up to Day 2 were collected within ± 10 minutes, within ± 2 hours from Day 3 to Day 21, within ± 1 day on Day 28, within ± 3 days from Day 42 to Day 180 and within ±5 days from Day 224 to Day 270. Serum concentrations of denosumab were measured at central laboratory by a validated analytical method.

    Time frame: 270 days

  2. Area Under the Drug Concentration-time Curve From Day 0 to Day 270 (AUC0-t) of ENZ215, EU- and US-sourced Prolia®. and EU- and US-sourced Prolia®

    A total of twenty four blood PK samples of 2.5 mL each were collected from each subject in the study. Pre-dose sample were collected within 30 minutes prior to IP administration. Post-dose samples up to Day 2 were collected within ± 10 minutes, within ± 2 hours from Day 3 to Day 21, within ± 1 day on Day 28, within ± 3 days from Day 42 to Day 180 and within ±5 days from Day 224 to Day 270. Serum concentrations of denosumab were measured at central laboratory by a validated analytical method.

    Time frame: 270 days

  3. Area Under the Drug Concentration-time Curve From Time 0 to Infinity (AUC0-inf) of ENZ215, EU- and US-sourced Prolia®. and EU- and US-sourced Prolia®

    A total of twenty four blood PK samples of 2.5 mL each were collected from each subject in the study. Pre-dose sample were collected within 30 minutes prior to IP administration. Post-dose samples up to Day 2 were collected within ± 10 minutes, within ± 2 hours from Day 3 to Day 21, within ± 1 day on Day 28, within ± 3 days from Day 42 to Day 180 and within ±5 days from Day 224 to Day 270. Serum concentrations of denosumab were measured at central laboratory by a validated analytical method.

    Time frame: 270 days

Secondary outcomes

  1. Partial Area Under the Drug Concentration-time Curve From Time 0 (Pre-dose) to Day 28

    AUC0-28 days were compared between ENZ215 and Prolia® using tests after log-transformation wherever appropriate.

    Time frame: 28 days

  2. Time to Reach Cmax (Tmax)

    The non-parametric analysis was used for the comparison of tmax between ENZ215 and Prolia®.

    Time frame: 270 days

  3. Terminal Elimination Half-life (t1/2)

    t1/2 was compared between ENZ215 and Prolia® using tests after log-transformation wherever appropriate.

    Time frame: 270 days

  4. Apparent Systemic Clearance (CL/F)

    CL/F was compared between ENZ215 and Prolia® using tests after log-transformation wherever appropriate.

    Time frame: 270 days

  5. Area Under the Effect Curve (AUEC) From Time 0 to Day 270 for Serum CTX-1 Percent Inhibition Percent Inhibition

    The AUEC was calculated as the area under the effect curve from baseline until CTX-1 values return to baseline for the first time. A total of sixteen (16) blood samples for serum CTX-1 estimation of 3.5 mL each was collected from each subject in the study. For CTX-1, blood samples were collected at the same time and after a minimum of 10 hours of fasting.

    Time frame: 270 days

Other outcomes

  1. Number of Subjects Who Developed Denosumab Neutralizing Antibodies and Antidrug Antibodies. Antibodies

    A total of 10 blood Immunogenicity assessment samples of 5.0 mL for NAb and ADA were collected from each subject in the study. The frequency and percentage of positive ADA or NAb result was provided. The proportion of positive ADA or NAb in each treatment group was compared using chi-square or Fisher's exact tests. The p-value, relative risk, and corresponding 95% CI was presented.

    Time frame: 270 days

  2. Incidence of Adverse Events

    Adverse events and SAEs as and when occurred, were properly recorded, evaluated, managed, and reported from signing informed consent till end of Study Assessment visit. All AEs were summarized using appropriate medical coding dictionary.

    Time frame: 270 days

07

Results

Posted Dec 23, 2025

Participant flow

Participant flow — Overall Study
MilestoneENZ215EU Sourced ProliaUS Sourced Prolia
Started686970
Completed666767
Not completed223

Outcome measures

PrimaryMaximum Observed Drug Concentration (Cmax) of ENZ215 and EU- and US-sourced Prolia®

A total of twenty four blood PK samples of 2.5 mL each were collected from each subject in the study. Pre-dose sample were collected within 30 minutes prior to IP administration. Post-dose samples up to Day 2 were collected within ± 10 minutes, within ± 2 hours from Day 3 to Day 21, within ± 1 day on Day 28, within ± 3 days from Day 42 to Day 180 and within ±5 days from Day 224 to Day 270. Serum concentrations of denosumab were measured at central laboratory by a validated analytical method.

Time frame:
270 days
Reported as:
Geometric mean · ng/ml
Maximum Observed Drug Concentration (Cmax) of ENZ215 and EU- and US-sourced Prolia®
ng/mlENZ215EU Sourced ProliaUS Licensed Prolia
Maximum Observed Drug Concentration (Cmax) of ENZ215 and EU- and US-sourced Prolia®7662.99 ± 32.67742.64 ± 23.28033.14 ± 24.9
PrimaryArea Under the Drug Concentration-time Curve From Day 0 to Day 270 (AUC0-t) of ENZ215, EU- and US-sourced Prolia®. and EU- and US-sourced Prolia®

A total of twenty four blood PK samples of 2.5 mL each were collected from each subject in the study. Pre-dose sample were collected within 30 minutes prior to IP administration. Post-dose samples up to Day 2 were collected within ± 10 minutes, within ± 2 hours from Day 3 to Day 21, within ± 1 day on Day 28, within ± 3 days from Day 42 to Day 180 and within ±5 days from Day 224 to Day 270. Serum concentrations of denosumab were measured at central laboratory by a validated analytical method.

Time frame:
270 days
Reported as:
Geometric mean · h*ng/mL
Area Under the Drug Concentration-time Curve From Day 0 to Day 270 (AUC0-t) of ENZ215, EU- and US-sourced Prolia®. and EU- and US-sourced Prolia®
h*ng/mLENZ215EU Sourced ProliaUS Licensed Prolia
Area Under the Drug Concentration-time Curve From Day 0 to Day 270 (AUC0-t) of ENZ215, EU- and US-sourced Prolia®. and EU- and US-sourced Prolia®7508134.18 ± 36.87674912.81 ± 24.97842297.13 ± 28.8
PrimaryArea Under the Drug Concentration-time Curve From Time 0 to Infinity (AUC0-inf) of ENZ215, EU- and US-sourced Prolia®. and EU- and US-sourced Prolia®

A total of twenty four blood PK samples of 2.5 mL each were collected from each subject in the study. Pre-dose sample were collected within 30 minutes prior to IP administration. Post-dose samples up to Day 2 were collected within ± 10 minutes, within ± 2 hours from Day 3 to Day 21, within ± 1 day on Day 28, within ± 3 days from Day 42 to Day 180 and within ±5 days from Day 224 to Day 270. Serum concentrations of denosumab were measured at central laboratory by a validated analytical method.

Time frame:
270 days
Reported as:
Geometric mean · h*ng/mL
Area Under the Drug Concentration-time Curve From Time 0 to Infinity (AUC0-inf) of ENZ215, EU- and US-sourced Prolia®. and EU- and US-sourced Prolia®
h*ng/mLENZ215EU Sourced ProliaUS Sourced Prolia
Area Under the Drug Concentration-time Curve From Time 0 to Infinity (AUC0-inf) of ENZ215, EU- and US-sourced Prolia®. and EU- and US-sourced Prolia®7622698.42 ± 36.47779487.60 ± 24.77934699.65 ± 28.9
SecondaryPartial Area Under the Drug Concentration-time Curve From Time 0 (Pre-dose) to Day 28

AUC0-28 days were compared between ENZ215 and Prolia® using tests after log-transformation wherever appropriate.

Time frame:
28 days
Reported as:
Geometric mean · h*ng/mL
Partial Area Under the Drug Concentration-time Curve From Time 0 (Pre-dose) to Day 28
h*ng/mLENZ215EU Sourced ProliaUS Sourced Prolia
Partial Area Under the Drug Concentration-time Curve From Time 0 (Pre-dose) to Day 283608894.44 ± 28.93721138.61 ± 20.63796048.41 ± 22.5
SecondaryTime to Reach Cmax (Tmax)

The non-parametric analysis was used for the comparison of tmax between ENZ215 and Prolia®.

Time frame:
270 days
Reported as:
Median · hours
Time to Reach Cmax (Tmax)
hoursENZ215EU Sourced ProliaUS Sourced Prolia
Time to Reach Cmax (Tmax)120.62 (47.22 to 360.63)120.08 (46.93 to 359.75)120.28 (46.98 to 479.92)
SecondaryTerminal Elimination Half-life (t1/2)

t1/2 was compared between ENZ215 and Prolia® using tests after log-transformation wherever appropriate.

Time frame:
270 days
Reported as:
Geometric mean · hours
Terminal Elimination Half-life (t1/2)
hoursENZ215EU Sourced ProliaUS Sourced Prolia
Terminal Elimination Half-life (t1/2)450.745 ± 28.3450.207 ± 23.2441.262 ± 27.1
SecondaryApparent Systemic Clearance (CL/F)

CL/F was compared between ENZ215 and Prolia® using tests after log-transformation wherever appropriate.

Time frame:
270 days
Reported as:
Geometric mean · mL/h
Apparent Systemic Clearance (CL/F)
mL/hENZ215EU Sourced ProliaUS Sourced Prolia
Apparent Systemic Clearance (CL/F)0.008 ± 36.40.008 ± 24.70.008 ± 28.9
SecondaryArea Under the Effect Curve (AUEC) From Time 0 to Day 270 for Serum CTX-1 Percent Inhibition Percent Inhibition

The AUEC was calculated as the area under the effect curve from baseline until CTX-1 values return to baseline for the first time. A total of sixteen (16) blood samples for serum CTX-1 estimation of 3.5 mL each was collected from each subject in the study. For CTX-1, blood samples were collected at the same time and after a minimum of 10 hours of fasting.

Time frame:
270 days
Reported as:
Geometric mean · h*%
Area Under the Effect Curve (AUEC) From Time 0 to Day 270 for Serum CTX-1 Percent Inhibition Percent Inhibition
h*%ENZ215EU Sourced ProliaUS Sourced Prolia
Area Under the Effect Curve (AUEC) From Time 0 to Day 270 for Serum CTX-1 Percent Inhibition Percent Inhibition432174.780 ± 20.1442806.204 ± 13.6436622.000 ± 18.6
Other pre-specifiedNumber of Subjects Who Developed Denosumab Neutralizing Antibodies and Antidrug Antibodies. Antibodies

A total of 10 blood Immunogenicity assessment samples of 5.0 mL for NAb and ADA were collected from each subject in the study. The frequency and percentage of positive ADA or NAb result was provided. The proportion of positive ADA or NAb in each treatment group was compared using chi-square or Fisher's exact tests. The p-value, relative risk, and corresponding 95% CI was presented.

Time frame:
270 days
Reported as:
Number · participants
Number of Subjects Who Developed Denosumab Neutralizing Antibodies and Antidrug Antibodies. Antibodies
participantsENZ215EU Sourced ProliaUS Sourced Prolia
ADA positive subjects686969
nAb positive subjects332
Other pre-specifiedIncidence of Adverse Events

Adverse events and SAEs as and when occurred, were properly recorded, evaluated, managed, and reported from signing informed consent till end of Study Assessment visit. All AEs were summarized using appropriate medical coding dictionary.

Time frame:
270 days
Reported as:
Count of participants · Participants
Incidence of Adverse Events
ParticipantsENZ215EU Sourced ProliaUS Sourced Prolia
Incidence of Adverse Events283932

Adverse events

Collected over from signing of informed consent to 270 days that is end of study. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ENZ2150/68 (0%)0/68 (0%)28/68 (41.2%)
EU Sourced Prolia®0/69 (0%)1/69 (1.4%)39/69 (56.5%)
US Licensed Prolia®0/69 (0%)0/69 (0%)32/69 (46.4%)
Most frequent serious events
Most frequent serious events
EventENZ215EU Sourced Prolia®US Licensed Prolia®
Ligament ruptureInjury, poisoning and procedural complications0/681/690/69
Most frequent other events
Showing 10 of 19
Most frequent other events
EventENZ215EU Sourced Prolia®US Licensed Prolia®
HeadacheNervous system disorders9/689/6914/69
NasopharyngitisInfections and infestations6/6811/6913/69
Upper Respiratory Tract InfectionInfections and infestations3/687/691/69
SARS-CoV-2 test positiveInvestigations2/686/691/69
ArthralgiaMusculoskeletal and connective tissue disorders1/684/690/69
HypocalcaemiaMetabolism and nutrition disorders3/683/692/69
RashSkin and subcutaneous tissue disorders3/680/690/69
ToothacheGastrointestinal disorders0/683/691/69
Skin abrasionInjury, poisoning and procedural complications0/683/690/69
InfluenzaInfections and infestations2/680/690/69

Baseline characteristics

Participants were healthy adult male volunteers between 28 to 55 years of age.

Age, Continuous
Age, Continuous(Years)ENZ215EU Sourced ProliaUS Licensed ProliaTotal
Mean37.9 ± 8.138.9 ± 7.740.1 ± 7.839.0 ± 7.9
Sex: Female, Male
Sex: Female, Male(Participants)ENZ215EU Sourced ProliaUS Licensed ProliaTotal
Female0000
Male686970207
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)ENZ215EU Sourced ProliaUS Licensed ProliaTotal
Asian1001
White676970206
Height
Height(cm)ENZ215EU Sourced ProliaUS Licensed ProliaTotal
Mean178.39 ± 6.22178.96 ± 6.44178.41 ± 7.69178.59 ± 6.79
BMI
BMI(kg/m^2)ENZ215EU Sourced ProliaUS Licensed ProliaTotal
Mean26.219 ± 2.60126.260 ± 2.76025.562 ± 2.83526.010 ± 2.740
Weight
Weight(kg)ENZ215EU Sourced ProliaUS Licensed ProliaTotal
Mean83.62 ± 10.7584.16 ± 10.3481.56 ± 11.6783.10 ± 10.94
08

Study locations

2 sites
  • MC Comac Medical
    Sofia, Sofia City Province 1000, Bulgaria
  • MTZ Clinical Research powered by Pratia, Pratia S.A
    Warsaw, 02-172, Poland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2022 to primary completion in May 2024, 28 months.

Results were first posted in Dec 2025, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2022
First posted
Feb 18, 2022
StartActual
Jan 10, 2022
Primary completionActual
May 22, 2024
CompletionActual
May 22, 2024
Results first posted
Dec 23, 2025
Last update
Dec 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05245669
Lead sponsor
Enzene Biosciences Ltd.
Collaborators
Alkem Laboratories Ltd
Responsible party
Sponsor
First posted
Feb 18, 2022
Start date
Jan 10, 2022
Primary completion
May 22, 2024
Completion
May 22, 2024
Results posted
Dec 23, 2025
Last update
Dec 23, 2025

Study contacts

Dr. Nadine Abdullah
principal investigator · Celerion GB Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion